Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Octreotide × NET × Clear all

Phase

Status

Completed 8 Recruiting 2 Active not recruiting 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2 Endocrine 2 Breast 2 NET 1 Head & Neck 1 Gastrointestinal 1

Conditions

Serotonin Syndrome 1 Neuroendocrine Tumors 1

Interventions

Everolimus 6 lutetium Lu 177 dotatate 3 surufatinib 2 lanreotide 2 gallium Ga 68 dotatate 2 dactolisib 2 Sunitinib 2 Magnetic Resonance Spectroscopy 2 Erlotinib Hydrochloride 2 Capecitabine 2 tislelizumab 1 pertuzumab 1 pembrolizumab 1 fosbretabulin 1 famitinib 1 entinostat 1 arginyllysine 1 amino-acid, glucose, and electrolyte solution 1 Surveys and Questionnaires 1 Somatostatin 1 Serotonin 1 Quality of Life 1 Panobinostat 1 Oxaliplatin 1 Ondansetron 1 Octreotide 1 Nivolumab 1 Leucovorin 1 LY2584702 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04140409 2019-10-25

SCIROCCO

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 4 Terminated

Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡